« Return to News | Awards & Advancement

Covance Names New Periapproval Services Executives

Monday, December 29, 2008 11:15 AM

Global contract research organization (CRO) Covance has added three new senior executive positions to its periapproval services team. The Princeton, N.J.-based company appointed Glynis Neagle, M.D., vice president for medical affairs; Robert Bader, director for product safety services; and Thomas Noto, vice president for regulatory affairs.

Neagle, who previously served as Covance’s senior director for clinical development, will oversee medical affairs, epidemiology and product safety.

Bader, formerly senior director for global pharmacovigilance and epidemiology at Cephalon, will lead phase IIIb and IV pharmacovigilance programs.

Noto, who has held various senior positions at other CROs, will oversee regulatory affairs.

Other personnel news from the clinical trial industry:

Cincinnati-based CRO Medpace named Bernard Ilson, M.D., medical director. An expert in nephrology with over 21 years experience in clinical drug development, Ilson served as chief medical officer of Cardiokine before joining Medpace.

Praxis, a Nashville, Tenn.-based patient recruitment company, appointed Megan Sturm business development manager, overseeing Praxis’ northeast U.S. and southern California territories. Sturm spent 14 years at Pfizer before joining Praxis in 2006.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.